Introduction {#Sec1}
============

The 'metabolic syndrome' (MetS) or 'syndrome X' is a constellation of cardiovascular risk factors including abdominal obesity, impaired glucose control, hypertension and dyslipidaemia \[[@CR1]\]. The MetS components separately increase the risk for cardiovascular disease (CVD) and all-cause mortality, but the full syndrome is associated with an increase in risk that is greater than the risk of each separate risk factor \[[@CR2]\]. Therapeutic lifestyle changes, including exercise, are recommended as firstline strategy in the treatment of cardiovascular risk factors \[[@CR3]\]. Previous meta-analyses demonstrated that dynamic endurance exercise decreases blood pressure (BP) in hypertensive individuals \[[@CR4], [@CR5]\], causes a significant reduction in blood lipids and lipoproteins in patients with hyperlipidaemia \[[@CR6], [@CR7]\], reduces glycated haemoglobin (HbA~1c~; percentage) in patients with type 2 diabetes mellitus \[[@CR7]\] and is associated with improved body composition in obese individuals \[[@CR7]\]. However, to the best of the authors' knowledge, meta-analyses have not been performed to determine the concomitant effect of exercise on all risk factors of the MetS in patients with the MetS.

Therefore, the aim of this study was to perform a systematic review with a meta-analysis of RCTs or CTs investigating the effect of exercise on cardiovascular risk factors in patients with the MetS.

Research Design and Methods {#Sec2}
===========================

Literature Search {#Sec3}
-----------------

We conducted a systematic literature search with the MEDLINE computerized database from its inception to November 2011 using the following medical subject headings (MeSH terms): 'Metabolic Syndrome X' AND ('Exercise' OR 'Motor Activities'). A second literature search was done in MEDLINE using the following title terms: 'Metabolic Syndrome' OR 'Syndrome X' AND 'Exercise'. In addition, the reference lists from published original and review articles were searched manually to identify other possible eligible studies.

Inclusion Criteria {#Sec4}
------------------

We included studies in the meta-analysis if the following requirements were met: (i) (RCTs) or CTs investigating the effect of exercise (dynamic endurance exercise---dynamic resistance exercise---or a combination); (ii) the duration of intervention was at least 4 weeks; (iii) intervention in adults (≥18 years) with the MetS (WHO 1998 \[[@CR8]\], National Cholesterol Education Program Adult Treatment Panel III \[NCEP/ATP III\] 2001 \[[@CR9]\] or International Diabetes Federation \[IDF\] 2005 \[[@CR10]\]) but with no other CVD; (iv) full publication in a peer-reviewed journal up to November 2011.

Measured Outcomes {#Sec5}
-----------------

The primary outcomes were changes in cardiovascular risk factors associated with the MetS: i.e. waist circumference (WC), fasting plasma glucose, systolic and diastolic blood pressure (SBP, DBP), high-density lipoprotein cholesterol (HDL-C) and triglycerides. Secondary outcomes included peak oxygen uptake ($\documentclass[12pt]{minimal}
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                \begin{document}$$ {\dot{{V}}\text{O}}_{{ 2 {\text{peak}}}} $$\end{document}$), body weight, body mass index (BMI), fat mass, total cholesterol, low-density lipoprotein cholesterol (LDL-C) and plasma insulin.

Data Extraction {#Sec6}
---------------

Two unblinded reviewers (N.P. and S.R.T.E.) independently conducted data extraction. A specifically developed data extraction sheet was used to extract data on study source, study design, characteristics of the participants, the exercise characteristics and the different outcomes in each study. Disagreements were solved by consensus or by a third reviewer (V.C.).

Study Quality {#Sec7}
-------------

Study quality was assessed using an adapted Physiotherapy Evidence Database (PEDro) scale \[[@CR11]\], which is an 11-item questionnaire designed to collect data on eligibility criteria, random allocation, concealed allocation, similarity of baseline values, blinding of therapists and/or assessors, key outcomes, intent-to-treat analysis, between group differences, and point and variability measures. We regarded the quality criteria 'blinding of participants' and 'blinding of therapists' as not applicable in exercise intervention studies, and omitted both criteria. All questions were binary (yes \[[@CR1]\] or no \[0\]). The minimum score was 0 and the maximum was 9, with a higher number reflecting a better study quality. The PEDro-scale has been reported to be valid and reliable \[[@CR12], [@CR13]\].

Statistical Analysis {#Sec8}
--------------------

Statistical analyses were performed using SAS^®^ version 9.3 (SAS Institute, Cary, NC, USA) and Review Manager Software (RevMan 5.1; Cochrane Collaboration, Oxford, UK). Descriptive data are reported as mean ± standard deviation (SD) or median and range. The mean baseline values were calculated by combining mean values from the intervention and control groups, weighted by the total number of participants in each study group. Since we worked with continuous data, we took the approach of assuming that randomization would adjust for baseline differences and used endpoint data only in the meta-analytical statistics. Each effect was weighted by the inverse of its variance. The results were combined using fixed and random effect models and presented with 95% confidence intervals (CI). Heterogeneity between trial results was tested with a standard Chi-squared (χ²) test. The I² parameter was used to quantify any inconsistency (I² = \[(Q − df)\] × 100%, where Q is the χ² statistic and df are the degrees of freedom). A value for I² \> 50% has been considered to be substantial heterogeneity. To examine the influence of each study on the overall results, analyses were also performed with each study deleted from the model. In addition, we performed a simple meta-regression analysis to investigate whether changes in the primary outcomes were related to changes in WC. Two-sided tests for overall effects were considered significant at p ≤ 0.05. Finally, funnel plots were used to assess the potential of small publication bias.

Results {#Sec9}
=======

Literature Search {#Sec10}
-----------------

From 822 potentially relevant studies retrieved from our search, 9 trials met our inclusion criteria \[[@CR14]--[@CR22]\]. A flow diagram of literature search and selection is presented in Fig. [1](#Fig1){ref-type="fig"}. Two studies were a duplicate of another study, i.e. using the same population and intervention, and so we included the most complete publication \[[@CR17]--[@CR19], [@CR22]\]. Hence, seven trials were included in the final analysis. Some of the trials applied different training regimens \[[@CR17], [@CR18]\] so that a total of nine dynamic endurance training interventions, one dynamic resistance training group and two combined dynamic endurance/resistance training groups were available for qualitative analysis. We used the meta-analytic techniques only on the nine dynamic endurance training groups.Fig. 1Prisma 2009 flow diagram

Characteristics of the Participants and Study Designs {#Sec11}
-----------------------------------------------------

Characteristics of the 12 included intervention groups are summarized in Table [1](#Tab1){ref-type="table"}. All studies were published between 2003 and 2010. Five of them were RCTs \[[@CR15], [@CR17], [@CR18], [@CR20], [@CR21]\] and two of them were CTs \[[@CR14], [@CR16]\]. Diagnosis of the MetS was based on WHO \[[@CR8]\] criteria \[[@CR14], [@CR18]\], ATP III \[[@CR9]\] criteria \[[@CR16]\] or IDF \[[@CR10]\] criteria \[[@CR17], [@CR20], [@CR21]\]. One trial \[[@CR15]\] used a mixture of the three definitions i.e. stage 1 or 2 hypertension (SBP 140--159 or ≥160 mmHg; DBP 90--99 or ≥100 mmHg); plasma insulin concentration greater than 80 μU/mL (\>556 pmol/L) 2 h after the ingestion of 75 g of glucose; dyslipidaemia, defined as high triglyceride (≥150 mg/dL; ≥1.7 mmol/L) and/or low HDL-C levels (men ≤40 mg/dL; ≤1.04 mmol/L, women ≤50 mg/dL; ≤1.3 mmol/L).Table 1Descriptive characteristics of the study groups at baseline and characteristics of the interventionStudy (year)Study designMetS criteriaMedicationGroupPre/post (n)Sex (M/F)Mean age (years)Duration (weeks)InterventionOutcomesDynamic endurance training Dumortier et al. \[[@CR14]\] (2003)CTWHO 1998NoEx28/287/21528F: 3×/weekMetS: WC, plasma glucose, HDL-C, TGCon11/114/753I: maximal lipid oxidation (defined by exercise calorimetry)Other: $\documentclass[12pt]{minimal}
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272 participants were randomized or allocated to an exercise group (dynamic endurance training, n = 147; dynamic resistance training, n = 11; combination, n = 32) or a control group (n = 82). Average drop out was 10% (range 0--33%), resulting in a total of 245 participants that could be included in the final analysis: 128 of them completed a dynamic endurance training intervention, 10 completed a dynamic resistance training intervention, 30 completed a combined intervention and 78 were control subjects.

Median age was 52 years (range 46--64). Six study trials included both men and women, and one trial included only women \[[@CR17]\] (±38% and ±41% males in the exercise and control group, respectively) \[[@CR15]\]. Four trials defined 'not being sedentary' as an exclusion criterion \[[@CR14]--[@CR17]\], while this was not specifically reported in the other three trials \[[@CR18], [@CR20], [@CR21]\]. Two trials did not report on diabetes status, four study trials excluded individuals with diabetes \[[@CR14]--[@CR17]\] whereas Balducci et al. \[[@CR20]\] included only MetS patients with diabetes. The use of medication was reported in three trials \[[@CR18], [@CR20], [@CR21]\]; antihypertensive agents, lipid-lowering agents and oral hypoglycaemic agents or insulin use were common pharmacotherapy treatments. Three other trials defined the use of medications as an exclusion criterion \[[@CR14], [@CR15], [@CR17]\]. Gomes et al. \[[@CR16]\] defined drugs known to affect lipoprotein metabolism as an exclusion criterion.

The 12 interventions lasted between 8 and 52 weeks (median 16). The frequency of training varied between two and five training sessions weekly (median 3), with an average of 47.5 min per session (range 40--60). All trials used walking, jogging or cycling as the modes of exercise. Two dynamic endurance training groups performed interval training \[[@CR18], [@CR21]\], while the other seven endurance training groups reported using a continuous training programme. Intensities ranged from moderate (e.g. 'maximal lipid oxidation') to high (e.g. intervals at 90--95% of heart rate peak \[HR~peak~\]). The exercise programmes were supervised in all studies except for Dumortier et al. \[[@CR14]\] where only the first training sessions were supervised and the patients continued the training at home afterwards.

In Table [2](#Tab2){ref-type="table"}, the results of the adapted PEDro-scale are represented. The median PEDro score was 6, with a range from 5 \[[@CR15], [@CR17]\] to 8 \[[@CR20]\].Table 2PEDro scores for the included intervention trialsStudy (year)Eligibility criteriaRandomly allocatedAllocated concealedSimilar baseline valuesBlinding of assessorsKey outcomes in 85% of included subjectsIntent to treatBetween-group statistical comparisonPoint + variability measureTotal PEDro scoreDumortier et al. \[[@CR14]\] (2003)1001011116Watkins et al. \[[@CR15]\] (2003)1101000115Gomes et al. \[[@CR16]\] (2008)1001011116Irving et al. \[[@CR17]\] (2008)1101000115Tjønna et al. \[[@CR18]\] (2008)1101010116Balducci et al. \[[@CR20]\] (2010)1111110118Stensvold et al. \[[@CR21]\] (2010)1111010117*PEDro* Physiotherapy Evidence Database

Primary Outcomes: Effect of Exercise on Cardiovascular Risk Factors Associated with the Metabolic Syndrome {#Sec12}
----------------------------------------------------------------------------------------------------------

Dynamic endurance training resulted in a mean reduction in WC of 3.36 cm (Fig. [2](#Fig2){ref-type="fig"}; baseline 104.62; 95% CI −4.87, −1.84; p \< 0.0001; I² = 35%), a mean BP decrease of 7.11 (Fig. [3](#Fig3){ref-type="fig"}; baseline 137.97; 95% CI −9.03, −5.18; p \< 0.0001; I² = 0%) mmHg/5.15 mmHg (Fig. [4](#Fig4){ref-type="fig"}; baseline 87.60; 95% CI −6.16, −4.13; p \< 0.0001; I² = 28%) and a mean increase in HDL-C of 0.06 (Fig. [5](#Fig5){ref-type="fig"}; baseline 1.04; 95% CI +0.03, +0.09; p \< 0.0001; I² = 38%) mmol/L. By contrast, levels of triglycerides (Fig. [6](#Fig6){ref-type="fig"}; −0.05; baseline 2.05; 95% CI −0.20, +0.09; p = 0.47; I² = 0%) mmol/L and plasma glucose (Fig. [7](#Fig7){ref-type="fig"}; −0.31; baseline 5.98; 95% CI −0.64, +0.01; p = 0.06; I² = 0%) mmol/L remained statistically unaltered.Fig. 2Average net changes and corresponding 95% confidence intervals for waist circumference. Tjønna et al. \[[@CR18]\] *A* and *B* represents moderate continuous training programme and aerobic interval training programme, respectively; and Irving et al. \[[@CR17]\] *A* and *B* represents high-intensity training and low-intensity training, respectively. *CI* confidence intervals, *df* degrees of freedom, *IV* intervention, *χ*^2^ Chi-squaredFig. 3Average net changes and corresponding 95% confidence intervals for systolic blood pressure. Tjønna et al. \[[@CR18]\] *A* and *B* represents moderate continuous training programme and aerobic interval training programme, respectively; and Irving et al. \[[@CR17]\] *A* and *B* represents high-intensity training and low-intensity training, respectively. *CI* confidence intervals, *df* degrees of freedom, *IV* intervention, *χ*^2^ Chi-squaredFig. 4Average net changes and corresponding 95% confidence intervals for diastolic blood pressure. Tjønna et al. \[[@CR18]\] *A* and *B* represents moderate continuous training programme and aerobic interval training programme, respectively; and Irving et al. \[[@CR17]\] *A* and *B* represents high-intensity training and low-intensity training, respectively. *CI* confidence intervals, *df* degrees of freedom, *IV* intervention, *χ*^2^ Chi-squaredFig. 5Average net changes and corresponding 95% confidence intervals for HDL-C. Tjønna et al. \[[@CR18]\] *A* and *B* represents moderate continuous training programme and aerobic interval training programme, respectively; and Irving et al. \[[@CR17]\] *A* and *B* represents high-intensity training and low-intensity training, respectively. *CI* confidence intervals, *df* degrees of freedom, *IV* intervention, *χ*^2^ Chi-squaredFig. 6Average net changes and corresponding 95% confidence intervals for triglycerides. Tjønna et al. \[[@CR18]\] *A* and *B* represents moderate continuous training programme and aerobic interval training programme, respectively; and Irving et al. \[[@CR17]\] *A* and *B* represents high-intensity training and low-intensity training, respectively. *CI* confidence intervals, *df* degrees of freedom, *IV* intervention, *χ*^2^ Chi-squaredFig. 7Average net changes and corresponding 95% confidence intervals for plasma glucose. Tjønna et al. \[[@CR18]\] *A* and *B* represents moderate continuous training programme and aerobic interval training programme, respectively; and Irving et al. \[[@CR17]\] *A* and *B* represents high-intensity training and low-intensity training, respectively. *CI* confidence intervals, *df* degrees of freedom, *IV* intervention, *χ*^2^ Chi-squared

To assess the effect of individual dynamic endurance studies on the summary estimate we performed a sensitivity analysis, in which the pooled estimates for the different outcomes were recalculated omitting one or two studies at a time. When we excluded the two aerobic interval training (AIT) studies, results were similar. However, when we omitted the only trial in which all patients had type 2 diabetes \[[@CR17]\], overall changes in DBP, HDL-C and WC were no longer statistically significant (p = 0.07; p = 0.44; p = 0.40, respectively).

The results of the meta-regression showed that decreases in DBP were significantly associated with reductions in WC (r = 0.91; p = 0.001). A non-significant trend was found for the association of WC with SBP (r = 0.67; p = 0.10) and for WC with HDL-C (r = −0.68; p = 0.06). triglyceride and plasma glucose were not related to changes in WC (p \> 0.20 for all).

Only one study investigated the effect of dynamic resistance training on components of the MetS \[[@CR21]\]. They reported a significant reduction of WC (from mean ± SD 111.5 ± 10.8 to 110.1 ± 11.0 cm; p \< 0.05) whereas HDL-C, triglycerides, plasma glucose, SBP and DBP remained statistically unaltered (p \> 0.05 for all).

Two trials, involving 33 participants investigated the effect of combined dynamic endurance and dynamic resistance training in patients with the MetS \[[@CR20], [@CR21]\]. Both trials observed a significant reduction of WC. In addition, Balducci et al. \[[@CR20]\] reported positive findings for HbA~1c~ (from mean ± SD 7.29 ± 1.35 to 6.34 ± 0.96%; p \< 0.0001) and HDL-C (from mean ± SD 44.1 ± 2.0 to 47.6 ± 1.85 mg/dL; p \< 0.001) whereas this remained statistically unaltered in the study of Stensvold et al. \[[@CR21]\]. Finally, none of the combined exercise studies found a statistically significant effect on triglycerides, SBP or DBP.

Secondary Outcomes: Effect of Dynamic Endurance Exercise on Other Cardiovascular Risk Factors {#Sec13}
---------------------------------------------------------------------------------------------

As shown in Table [3](#Tab3){ref-type="table"}, dynamic endurance training also positively affected other blood lipids (LDL-C, total cholesterol), some anthropometric characteristics (body weight, BMI) and resulted in a significant increase of $\documentclass[12pt]{minimal}
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Publication Bias {#Sec14}
----------------

Funnel plots did not show any significant publication bias for all of the primary and secondary outcomes, meaning that there was no asymmetric relationship between treatment effects and study size (data not shown).

Discussion {#Sec15}
==========

The main findings of this meta-analysis suggest that in patients with the MetS, dynamic endurance training is associated with favourable effects on most cardiovascular risk factors related to the MetS, that is WC, HDL-C, SBP and DBP. Our results further demonstrate that in these patients dynamic endurance training also favourably affects other important cardiovascular risk factors including LDL-C, total cholesterol, BMI and $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {\dot{{V}}\text{O}}_{{ 2 {\text{peak}}}} $$\end{document}$.

It is generally accepted that we need better and more affordable prevention and treatment strategies to improve wide-scale cardiovascular health outcome and to prevent the epidemic of MetS from reaching global proportions and straining public health and the economy \[[@CR18]\]. Exercise is a key component in the treatment of patients with the MetS and in the prevention of CVD morbidity and mortality. The results of this study are in line with previous meta-analyses and extensive reviews that focused on the effect of exercise on single risk factors in populations with different cardiovascular risk factors \[[@CR4]--[@CR7]\].

First of all, we observed a significant improvement in measures of body composition including reduction in abdominal obesity, assessed by means of WC, body weight and BMI and a non-significant reduction in fat mass. Improvements in body composition characteristics are suggested to be associated with beneficial changes in lipids and lipoproteins through mechanisms related to insulin resistance \[[@CR23], [@CR24]\]. Indeed, the results of our meta-regression show a trend (p = 0.06) between changes in WC and HDL-C. In line with the meta-analysis of Kelley et al. \[[@CR25]\], we observed significant increases in HDL-C and decreases in LDL-C and total cholesterol, without an effect on triglycerides. Wilson et al. \[[@CR26]\] found that an HDL-C level between 41 and 46 mg/dL (1.06--1.19 mmol/L) for men resulted in a relative risk (RR) of all-cause death of 1.27 and HDL-C levels between 23 and 44 mg/dL (0.59--1.14 mmol/L) in an RR of 1.47 for women, compared with groups with values of more than 55 and 70 mg/dL, respectively. In our meta-analysis, HDL-C levels rose from 1.05 mmol/L to 1.13 mmol/L in a sex-mixed population, still showing non-optimal HDL-C plasma levels. However, it is stated in a meta-analysis of Kelley et al. \[[@CR25]\] that a decrease of 1% in HDL-C would be associated with an increase in the risk for coronary heart disease of 2--3%. Assuming that the reverse is true, the approximate increase of 8% observed in our meta-analysis should decrease the coronary heart disease risk by 16--24%.

In addition, patients with the MetS do have type 2 diabetes or at least have an increased risk for developing it. Whereas plasma insulin levels remained statistically unaltered, we observed a trend towards lower values of mean plasma glucose following dynamic endurance exercise (p = 0.06). Earlier, Snowling and Hopkins \[[@CR27]\] reported in patients with type 2 diabetes significant reductions in fasting glucose, HbA~1c~ and insulin sensitivity after dynamic endurance training, with some evidence of small additional benefits resulting from combining endurance and resistance training. Moreover, it was suggested that the effects were somewhat larger for those with a more severe disease status, in particular for HbA~1c~. The lack of a significant effect on glucose-insulin dynamics in the current meta-analysis might be partly explained by the fact that the majority of participants were pre-diabetic but did not have diabetes. Indeed, the study of Balducci et al. \[[@CR20]\] in patients with type 2 diabetes and the MetS did result in significant decreases in HbA~1c~ after 12 months of exercise training, which confirms our suggestion. In addition, measuring plasma glucose and plasma insulin after an oral glucose tolerance test is often a better marker of changes in glucose tolerance after an exercise or dietary intervention. In the study of Watkins et al. \[[@CR15]\], significant decreases in 2 h of plasma insulin were found in the dynamic endurance exercise group but not in the control group after 26 weeks, while there were no changes in fasting glucose and fasting insulin.

Following dynamic endurance training, a mean reduction in BP of 7/5 mmHg was achieved. These mean differences are statistically significant but more importantly, the magnitude of these differences is likely to be clinically relevant. Results from large, prospective intervention studies suggested that small reductions in resting SBP and DBP of 3 mmHg can reduce coronary heart disease risk by 5%, stroke by 8% and all-cause mortality by 4% \[[@CR28]\].

Although the observed effect on each of the individual risk factors might seem small, when we combine all the effect sizes, that is a BP reduction to a mean of 131/82 mmHg, a decrease in WC to an average of 101 cm and for plasma glucose and triglycerides to a mean of 5.67 and 2.0 mmol/L, respectively and an increase of HDL-C to 1.1 mmol/L, a large number of patients would probably no longer be classified as having the MetS. Earlier, Katzmarzyk et al. \[[@CR29]\] showed that 30.5% of patients (mean age 44.7 years) with the MetS at baseline, were no longer classified as having the MetS after a 20-week supervised dynamic endurance training programme. This reduction was mostly due to an improvement in triglycerides (43%), BP (38%) and WC (28%) whereas beneficial effects on HDL-C and plasma glucose were seen in fewer patients (16 and 9%, respectively). Similarly, Anderssen et al. \[[@CR30]\] reported that 23.5% of 34 patients no longer had the MetS after an exercise intervention of 1 year. The only study included in this meta-analysis reporting on the number of patients with the MetS showed similar decreases with a 37.5% (from 8/8 to 5/8) and a 45% decrease (from 11/11 to 6/11) following 16 weeks of continuous and interval training, respectively \[[@CR18]\]. Although it is difficult to quantify exactly the overall risk reduction associated with all observed changes, these results are compatible with an overall improvement of cardiovascular risk. Moreover, the results of this meta-analysis study are supported by studies that have examined the cross-sectional relationship between physical activity and the MetS. For example, in 1298 healthy police employees of the Utrecht Police Lifestyle Intervention Fitness and Training (UPLIFT) study, average physical activity intensity, average time spent at physical activity, physical activity volume and physical fitness, were each associated with reduced odds of the MetS \[[@CR31]\]. Taken together, the results of these studies, and those from the present meta-analysis, reinforce the notion that physical activity is an important treatment option for the MetS, as stated in Katzmarzyk et al. \[[@CR29]\].

Finally, low aerobic capacity has been shown to be a stronger predictor of CVD and mortality compared with other established risk factors \[[@CR32]\]. The five studies that reported on the effect of dynamic endurance training on $\documentclass[12pt]{minimal}
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                \begin{document}$$ {\dot{{V}}\text{O}}_{{ 2 {\text{peak}}}} $$\end{document}$ showed a significant mean increase of 6 mL/kg/min or 19.3%. An increase of one metabolic equivalent task (=3.5 mL O~2~/kg/min) in exercise capacity referred to an RR for all-cause death of 0.84 \[[@CR33]\]. Earlier, physical activity and physical fitness have been shown to be inversely associated with the clustering of metabolic abnormalities \[[@CR31]\]. With regard to physical activity, it seems that intensity and more specifically higher intensity is the main characteristic of physical activity determining its effect on the combination of CVD risk factors \[[@CR31]\]. However, as physical fitness exerted greater effects \[[@CR31]\], this suggests that in daily practice physical activity should preferably increase physical fitness to maximize its effect on the prevention of the MetS. This might most likely be achieved by exercise at higher intensity \[[@CR31]\]. Given the lack of adequate reporting of training characteristics, we were unable to investigate the effect of intensity in this meta-analysis. A considerable number of additional studies will be required to adequately discuss this aspect.

With regard to the effect of other training characteristics on cardiovascular risk factors in patients with the MetS, more research is warranted to allow for appropriate exercise prescriptions. That is, only one intervention group investigated the effect of dynamic resistance training on the clustering of cardiovascular risk factors in individuals with the MetS and found that only WC was decreased significantly \[[@CR21]\]. In a study of Banz et al. \[[@CR34]\], with obese subjects, the effect of dynamic resistance training also resulted in significant changes in WC, but in no other significant beneficial cardiovascular effects. Smutok et al. \[[@CR35]\] found significant changes in glucose and insulin responses after an oral glucose tolerance test was administered after a dynamic resistance training programme in individuals with two cardiovascular risk factors, but blood lipids and lipoproteins or BP outcomes didn't improve significantly. It seems that dynamic resistance training has potential beneficial effects on the cardiovascular risk profile, but that dynamic endurance training is more beneficial \[[@CR34], [@CR35]\]. In a large meta-analysis of Cornelissen et al. \[[@CR36]\], the effect of resistance training on BP and other cardiovascular risk factors was reviewed. They found positive effects on SBP, DBP and $\documentclass[12pt]{minimal}
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The effect of combined exercise on the clustering of cardiovascular risk factors in patients with MetS was discussed in two studies \[[@CR20], [@CR21]\]. Balducci et al. \[[@CR20]\] concluded that combined endurance and resistance training had larger beneficial effects on upper body strength and body weight than dynamic endurance training only. No significant differences were found for the other outcome measures \[[@CR20]\]. Stensvold et al. \[[@CR21]\] found slightly larger benefits for the dynamic endurance training on SBP and DBP than that of combined exercise. The training responses were similar for WC, HDL-C, triglycerides and plasma \[[@CR21]\]. However, more research is needed to investigate the potential benefits of combined training programmes.

The results of this meta-analysis should be interpreted within the context of its limitations: First, only one study fulfilling the inclusion criteria included a dynamic resistance intervention \[[@CR21]\], and only two trials used a combined intervention of dynamic resistance training and endurance training \[[@CR20], [@CR21]\]. Further research about the effect of dynamic resistance training only or in combination with dynamic endurance exercise training is warranted in patients with the MetS. Second, a sensitivity analysis demonstrated that omitting the only trial in which all patients had type 2 diabetes \[[@CR20]\], the effect of exercise on DBP, HDL-C and WC were no longer significant (p = 0.07; p = 0.44; p = 0.40, respectively). The severity of the MetS risk factors or a pathological state (type 2 diabetes) can probably influence the effects of exercise training, with more severe CV risk factors resulting in potentially larger improvements. Third, due to the small number of study groups, a subgroup analysis for sex or medication intake was not possible. More research is needed on the effect of variables that could potentially affect the outcomes of an exercise programme, especially the effect of sex and medication. Further, the mean age of participants was 52 years with a range between 46 and 64 years; therefore it may not be possible to generalize these results for younger or older individuals with the MetS. Finally, it has been suggested that one exercise dose does not fit for all components of the MetS and that recommendations should vary regarding the different risk factors \[[@CR37]\]. Therefore, it is necessary to strike a balance for the most optimal exercise programme to improve the cluster of cardiovascular risk factors in patients with the MetS.

Conclusion {#Sec16}
==========

It can be concluded that exercise interventions have beneficial effects on most of the cardiovascular risk factors in patients with the MetS, but further research is needed to expand the knowledge and to strengthen the results found in this meta-analysis.
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